HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research report sent to ...

HC Wainwright reaffirmed their buy rating on shares of Endeavour Silver (NYSE:EXK – Free Report) (TSE:EDR) in a research ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Poseida Therapeutics ...

Although it has lowered in recent days, commentators were mostly positive, with one hold and four buy recommendations on the stock. The consensus rating for the stock, as classified by MarketBeat, is ...

Fintel reports that on November 13, 2024, HC Wainwright & Co. downgraded their outlook for BioAtla (NasdaqGM:BCAB) from Buy ...

Wall Street expects Bitcoin miner CleanSpark Inc (NASDAQ:CLSK) to report a loss of 18 cents per share and $88.65 million in ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...

Fintel reports that on November 6, 2024, HC Wainwright & Co. initiated coverage of BitFuFu (NasdaqCM:FUFU) with a Buy recommendation. There are 9 funds or institutions reporting positions in BitFuFu.

HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months.

Reiterates HC Wainwright & Co.: Neutral to Neutral 11/11/2024 Maintains HC Wainwright & Co.: Neutral to Neutral 8/12/2024 Reiterates HC Wainwright & Co.: Neutral to Neutral 6/17/2024 Maintains HC ...